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- Neuroblastomas are the second most 
common malignant tumor in 
childhood
- Children with this disease have a poor 
prognosis with the 5 year survival 
rate being less than 50%
- Even with intense chemoradiotherapy 
children have a high fatal relapse 
rate and long term survival rate of 
merely 25%
N-(4-Hydroxyphenyl)- retinamide
Retinoids have been research extensively in vitro regarding 
neuroblastoma and under recent years have been used in 
clinical investigation.
In Vitro studies that have been conducted demonstrated that 4HPR 
can suppress malignant tumor growth associated with induced 
apoptosis. This includes Neuroblastomas and it is believed that 
administration of this drug over a long-term period may 
prevent relapse of the disease. This is essential in 




Preclinical Phase 1 Phase 2 Phase 3
Lab Studies Human Safety Expanded Safety Efficacy & Safety
Methods
02
Stage 4 in second or further 
complete remission
Patient Eligibility
Patients older than 12 months with 
stage 3 or 4 neuroblastomas with a 
high risk of developing a progressive 
disease of relapsing
Partial remission at the end 
of treatment
Resistant disease
This timeline occurred for up to 6 courses, with three patients entering 
escalating 4HPR levels
Trial Timeline
DAY 1 DAY 28 DAY 35
For 28 days, 54 patients received 4HPR orally. The starting 
dose was 100 mg/ mg2/day. 
Pharmacokinetic samplingPharmacokinetic sampling
7 – day interruption to 





- Toxic effects observed in 34 of 53 
patients and most commonly observed 
were skin xerosis and nyctalopia
- 12 patients showed early progression 
of the disease during the first course of 
treatment
- The disease remained stable 24 
patients but died after disease 
progression
- 17 still living patients without disease 
progression
Conclusion
- It was determined that oral 
administration oce a day for 28 days 
followed by a 7 day discontinuation is 
better tolerated than continuous 
treatment
- This drug has no effect on patients 
with massive disease setting 
(advanced Neuroblastomas and those 
in relapse)
Patients who were treated with 4HPR 
in a PR phase showed prolonged 
stabilization of the disease, and 
some of them showed regression of 
some lesions.
Favorable effects occurred more 
frequently in patients who received 
doses of 4HPR of 1000 mg/ m2/day 
or higher and whose plasma levels 
where above 5 M after repeated 
treatment.
It can be said that a Phase II study 
testing 4HPR as possible 
maintenance therapy for the control 
of minimal disease in 
neuroblastoma would be 
warranted.
Results
● Do you believe Fenretinide is warranted to use in children with Neuroblastomas?
○ Should there be a Phase II trial as discussed in the conclusion?
● What do you think about drug trials involving children with progressive malignant 
tumor diseases?
● What do you think should be the next step in the trial, should it be continued?
● What do you think about using retinoids to treat cancer.
● Does the length of a drug trial have any impact on the validity of the results?
Discussion Questions
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